• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Bristol Myers Squibb Expands at Cambridge Crossing

    Amgen Completes Five Prime Acquisition

    Sartorius Expands in the UK

    Obituary Notice: Russell “Russ” Haines

    Abenza Chooses North Carolina for New Biologics Manufacturing Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Recro, Ensysce Expand Development and Manufacturing Partnership

    Metrics Names Stephanie Emory Associate Director of Pharma Development

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Obituary Notice: Russell “Russ” Haines

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Bristol Myers Squibb Expands at Cambridge Crossing

    Amgen Completes Five Prime Acquisition

    Sartorius Expands in the UK

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Arkema Recruits Dotmatics as its R&D Digitalization Partner
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    PCI Pharma Services

    Emergent BioSolutions

    Syngene

    Aphena Pharma Solutions

    Quotient Sciences
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Quotient Sciences

    Baxter BioPharma Solutions

    Adare Pharma Solutions

    Syngene

    Reed-Lane
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Preparing Your Post Pandemic Talent Strategy

    Areas for consideration for adopting the right approach to reinforce investments, optimize business and maximize your workforce.

    Preparing Your Post Pandemic Talent Strategy
    Neil Kelly, Managing Partner, Vector Partners04.01.21
    What has changed during the pandemic? Pharma companies currently face many opportunities. Increased profits are one result of the continued surge in demand from Covid-19 related activities. Investors are now pushing CEOs and their leadership teams to reveal their road maps for the future. That is, how they will best utilize the current business environment and maintain momentum for further sustainable growth. For leadership teams today, linking business strategy, organizational design and operational delivery will create the path to success, driven by people.

    The pharma industry has seen a surge in organizations deciding to act fast on acquisitions that they have long been exploring and moving quickly to finalize in 2020/21 fiscal years. Those acquisitions have been driven by the need to service the demand requests from customers, particularly vaccine manufacturing capacity. Organizations who are taking on new facilities and don’t have a well-oiled mergers and acquisitions (M&A) talent strategy, can find themselves quickly stuck with many challenges, for both the purchaser and acquirer. Throw in a pandemic and this magnifies issues.

    Competition among contract development and manufacturing organizations (CDMOs) has increased exponentially due to a number of factors driven by smart investors, demand, Big Pharma refocusing and a sharp increase in new innovative molecules hitting the market. The pandemic has significantly pushed this demand for even more capacity, which is set to continue.

    A less publicized impact from increased competition is the impact on talent. The availability of talent in the market has been significantly strained, and now stands at a critical point in some geographical regions.
    In order to demonstrate this point, Big Pharma managed to hire talent mostly through strong internal talent development programs historically. New technologies, digitalization and innovation are creating the perfect storm for organizations to navigate, requiring a rapid rethink of how they hire and develop the next generation of employees, which is driving greater levels of external hiring.

    Aftershocks of Covid-19 on talent supply chain
    The pandemic is now compounding the talent issue. As organizations accelerate their expansion plans, growth plans are often not aligned to the available external workforce.

    The greatest operational impact has been felt by the pharma manufacturing sites, where the employee cannot be based remotely, as they are part of the production at a specific location. These sites were hit the hardest in those areas, who experienced the highest levels of Covid infections, which required smart planning on behalf of those leadership teams. One key outcome has been of organizations to think about how and where work gets done, some organizations are insisting all employees needs to be back on site, while others are maintaining remote working as benefit to the employee.

    Mobility of talent of has been impacted throughout this pandemic, with less people physically being able to move through country restrictions. Although what is unclear is the longer-term impact of talent mobility across the globe, mostly driven by country specific restrictions, candidate behaviors and potentially unwillingness to move. Early studies suggest that people travelling much less will be a trend that may continue, resulting in more hyperlocal mobility and even less talent considering a relocation. This trend is forcing sites and companies to think differently, considering things like ‘virtual assignments’, staying in the home location, while working in the same time zone where the work is being delivered.

    Impact to organizational design, talent and recruitment costs
    Many organizations who are on a growth journey, are trying to facilitate this growth with a business model that is localized. Most organizations have a collection of smaller P&L’s from country legal entities, which are often a result of legacy acquisitions. Many organizations opt for fewer resources that sit in the ‘center’. The decision of the operating model creates an impact to an organization’s ability to hire the right talent in an effective and sustainable way to drive their growth, as they often are unable to easily leverage expertise, resources and internal talent.

    As a result of this structure, many organizations will have a patchwork of how they attract and develop talent; those bigger organizations are leveraging their scale, while a smaller sites may suffer. This model becomes very exposed when talent dries up locally, requiring them to go outside of commutable distance. This often results in leadership to start taking knee jerk decisions on hiring, often resulting in chaotic costly decision when managing recruitment agencies, throwing more and more investment to deal with the challenge. Although rarely organizations stop to ask the question if there is another way to manage talent resources more effectively, building the availability of talent into an organization’s investment decisions, leveraging more sophisticated market and talent insights.

    Finding your purpose and power of employer brand
    Many organizations in pharma often underplay their role in people’s lives, often as a symptom of operating in a highly regulated environment, historically have opted for a more conservative approach to branding. In other cases, they struggle to establish an employer brand, often citing that it is too expensive and no possible return on investment, as they are a business-to-business service offering.

    Through Covid-19 all organizations minds were quickly focused on their purpose and the CDMO market thrust into the limelight. Since most CDMO companies never even had a structured communications plan, let alone an employer brand, never would have anyone guessed that this highly unusual situation would expose this frailty.

    Big Pharma was able to do better than CDMOs overall, because they had the infrastructure to handle the surge in communications. Although what was surprising was the role that the employer brand teams played through this crisis, often followers of these companies tracked news through social media channels, historically used for recruitment branding.

    This gave a compelling reason for marketing and employer brand to work collaboratively, demonstrating how crucial the need to integrate messaging is to the external market and the key role employer branding can play in your organization.

    Building an employer brand requires a very specific skill set, although has many advantages. Here are the top 5 reasons why every organization needs to build an integrated employer brand:
    1. Attract and retain the right talent
    2. Drives the most qualified candidates
    3. Decrease cost per hire on average 43%
    4. 69% of candidates are more likely to apply with a well-managed employer brand
    5. Builds internal brand advocacy with existing employees

    How to win the war for talent with your talent strategy
    The new reality created by Covid-19 has required a revision of business strategies, which is requiring a shake-up of talent strategies and leadership teams asking if one even exists? Understanding the required skills needed to execute an organizations business strategy successfully to make the company stand out from the crowd of competitors and ensure compliance are just some of the benefits that this structured approach creates.

    Understanding the blend of skills required to deliver the objectives is critical, which then drives the optimum operating model, leading to the right blend of skills, carrying out an inventory of the required skills is often necessary. Although companies too frequently focus on permanent headcount as a fixed cost. Contingent labor is often overlooked, because variable labor information is more difficult to collect, it can be surprisingly costly—often consultants and embedded delivery of services can be overlooked. Establishing this can also help with a key issue: understanding how work gets done in your organization. Smarter ways of managing contingent labor effectively can save minimum 10% of its cost, which allows organizations to make investments from these savings in systems, that can give prompt and accurate information about the total workforce, including your non payrolled population.

    The talent strategy should also consider the necessary technology that complements the workforce. The right combination of systems, applications, automation, artificial intelligence and team delivering this activity, highly influences the efficiency of an organization. Workforce related technologies are booming and creating real opportunities for companies to build competitive advantage, although having a well thought out plan for technology is critical, otherwise decisions can become very expensive very quickly.

    While stepping through this process of considering new skills and technologies, companies will identify unnecessary positions that are going to become obsolete in the future, all too often organizations continue to recycle what they have always done. If the skills are identified early enough, then companies have time to reallocate resources, reskill their people and minimize restructuring.

    During the talent strategy work it is important that cost analysis takes place to understand the costs and benefits of every strategic choice. At the end the talent strategy will reveal the necessary organizational changes and projects that will attract, engage and retain the necessary talent.

    Recommendations to CDMOs
    All talent related actions should be delivered within the context of your organization and budget—prioritize the business objectives always, never compromise the quality of product delivery. While there are no two talent strategies the same, there are some consistent themes, especially translating the business strategy into a meaningful outcome-focused talent approach.

    CDMOs and Big Pharma compete for the same talent. Although, CDMOs need to play to their strengths in order to attract talent. Generally, they are smaller and therefore can be more agile in decision making, than their Big Pharma counterparts. Talent potentially can have broader range of responsibilities, being involved in many projects, rather than one single track. Find who you really are, what makes your organization unique and put it in the window.

    Remote work has gained popularity and became more and more common practice. It allows companies to tap into talent pools in remote locations. It’s likely we will see an uptick in those organizations who do not offer remote working or flexible working, post pandemic. Building an infrastructure that facilitates work and collaboration between people distanced is the name of the game. Go beyond Zoom!
    Here are five questions every organization should be asking:
    1. Do you have a forward plan for hiring?
    2. How much did you spend on recruiting your talent last year?
    3. How many vacancy openings do you have today and how long have they been open?
    4. Are you confident the hires you are making are bringing the right skills to your organization to deliver on your objectives?
    5. Do you know what candidates think about your employer brand in the market?

    Why is this important?
    • Better planning leads to smarter investment decisions.
    • Understanding what you need well, allows you to be more specific in skills required.
    • The longer you have vacancies open the more of an impact on your revenue this creates.
    • If you were launching a new service into the market you would always invest the time, cost and energy into insight prior to launching. This is no different, when attracting talent.
    • Empty vacancies lead to lost revenue.

    Lastly, if you want to build a structured talent approach, you need to review how you are currently hiring your workforce. This is a specialist capability, requiring highly capable talent resources, who are able to assist you in the set up and management of the talent strategy, organizational design, succession planning, recruitment, employer branding, onboarding, diversity and inclusion, technology and analytics solutions. This initiative if you choose to take it on, should always be outcome-focused, working seamlessly to deliver your business objectives.

    Now is the time for CDMOs to think and act for the long-term about their future talent. More disciplined talent strategies with practical, laser-focused plans and rapid, agile execution are the ingredients of the ‘secret sauce’ for success. Expect the rush for talent to intensify when the global economy grows again. Don’t wait. Act now! 

    References
    • https://www.bdo.com/insights/tax/global-employer-services/the-future-of-global-mobility-in-a-post-covid-(2)
    • https://linkhumans.com/employer-branding-important/
    • https://home.kpmg/xx/en/home/insights/2020/08/flexibility-and-agiliity-post-covid-19.html


    Neil Kelly is the Co-Founder and Managing Partner of Vector Partners. Neil established Vector Partners in 2020 to provide talent advisory services to drive smart, cost-effective hiring and growth of science innovators, leveraging his own deep CDMO and Pharma experience. Vector’s vision is to shake up how leadership teams think about hiring, taking an integrated approach to talent while delivering innovative recruitment approaches to solve organizational talent challenges.

    Related Features

    • R&D
      Small Innovators & Niche CROs

      Small Innovators & Niche CROs

      Smaller CROs have the opportunity to provide a niche approach to its clients, particularly smaller sponsors who have shared synergies.
      Neil Goodman, David Bruce and Mohamed El Malt, Europital 04.01.21

    • Laboratory Testing
      Focus on Science

      Focus on Science

      How to maximize lab performance and value through comprehensive equipment management.
      Rohit Shroff, Senior Vice President, Global Lab Products, Avantor 04.01.21

    • Analytical Services | Bioanalytical Services | Laboratory Testing | R&D
      Rapid and Data Rich Chromatographic Method Development

      Rapid and Data Rich Chromatographic Method Development

      An overview of what to consider when developing chromatographic methods.
      Daniel Kirschner, Executive Director of Analytical Services, Cambrex - Durham, North Carolina 04.01.21


    • Laboratory Testing | R&D
      How Modern Near-Infrared Came to Be

      How Modern Near-Infrared Came to Be

      First region outside the visible to be discovered and last to be utilized.
      Gary E. Ritchie, Contributing Writer 04.01.21

    • APIs | Supply Chain
      Securing Your API Supply Chain: Three Keys to Success

      Securing Your API Supply Chain: Three Keys to Success

      Key considerations when outsourcing API procurement and supply chain management.
      Selwyn Lustman and Lina Cogan, LGM Pharma 04.01.21

    • Solid Dosage/Semi-solids
      Hygienic Packaging Technology

      Hygienic Packaging Technology

      Growing consumer demand for health products highlights hygienic packaging.
      John Brown, Vice President of Global Marketing, Selig 03.01.21


    • Drug Delivery | Solid Dosage/Creams/Ointments
      Trends in Solid Oral Dosage Delivery

      Trends in Solid Oral Dosage Delivery

      Capsule demand continues to rise due to this delivery system’s versatility.
      Anita Solanki, Milind Biyani and Jnanadeva Bhat, PhD , ACG Capsules 03.01.21

    • Information Technology
      5 Reasons Paper Has No Place in Contract Manufacturing

      5 Reasons Paper Has No Place in Contract Manufacturing

      Digital solutions create more efficient manufacturing processes and eliminate delays.
      Dave Edwards, Chief Revenue Officer, MasterControl 03.01.21

    • Drug Delivery | Parenterals
      Injectable Drug Delivery Trends

      Injectable Drug Delivery Trends

      How medication trends are driving the shift to patient-friendly drug delivery systems.
      Peter Soelkner, Managing Director, Vetter 03.01.21


    • Pharmaceutical Manufacturing  Equipment Trends

      Pharmaceutical Manufacturing Equipment Trends

      Demand for flexibility remains the driving force behind equipment systems.
      Kristin Brooks, Managing Editor, Contract Pharma 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Oral Solids:   Market & Technology Trends

      Oral Solids: Market & Technology Trends

      Oral solids remain the preferred route of drug delivery due to their cost-effectiveness, ease of manufacturing, and patient-friendly dose form options.
      Tim Wright, Editor, Contract Pharma 03.01.21

    • Nutraceutical Manufacturing:  Meeting the Challenges of Today, Planning for  Tomorrow

      Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow

      Companies continue balancing high demand, supply disruption, and worker safety during the pandemic.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21


    • 2021 Contract  Manufacturing Survey

      2021 Contract Manufacturing Survey

      Our fourth annual audience poll indicates continued reliance on manufacturing partners, particularly for small businesses.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • APIs
      Small Molecule Development Trends

      Small Molecule Development Trends

      A Q&A with Cambrex Edinburgh’s site director, Mark Benger.
      Tim Wright, Editor, Contract Pharma 03.01.21

    • APIs | Cytotoxics and High Potency Manufacturing
      Challenges & Opportunities Facing Small & Emerging Biopharma Companies

      Challenges & Opportunities Facing Small & Emerging Biopharma Companies

      A Q&A with Christian Dowdeswell, vice president and head of commercial development for small molecules at Lonza.
      Tim Wright, Editor, Contract Pharma 03.01.21

    Trending
    • Thermo Fisher Acquires PPD For $17.4B
    • Abenza Chooses North Carolina For New Biologics Manufacturing Site
    • Executive Moves: Novavax
    • Ensuring Pharma Manufacturing Quality
    • Sanofi Invests In Cutting Edge Vax Production Site In Singapore
    Breaking News
    • Bristol Myers Squibb Expands at Cambridge Crossing
    • Amgen Completes Five Prime Acquisition
    • Sartorius Expands in the UK
    • Obituary Notice: Russell “Russ” Haines
    • Abenza Chooses North Carolina for New Biologics Manufacturing Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    AstaReal Astaxanthin Ingredient Receives U.S. Patent Approval
    Study on Kemin’s DailyZz Botanical Blend Uncovers Sleep Quality, Next-Day Performance Benefits
    FDA’s Dr. Cara Welch Opening Speaker at the 9th AHPA Botanical Congress
    Coatings World

    Latest Breaking News From Coatings World

    Jebsen & Jessen, Innospec Sign Distribution Agreement
    IGL Coatings Announces Partnership in Finland
    Axalta Schedules 1Q 2021 Earnings Conference Call
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Iterative Scopes Announces IBD-Focused Scientific Advisory Board
    Vicarious Surgical, D8 Holdings Corp. Combine Operations in $1.1 Billion Deal
    FDA Grants De Novo Clearance to Medtronic’s GI Genius Model
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Bristol Myers Squibb Expands at Cambridge Crossing
    Amgen Completes Five Prime Acquisition
    Sartorius Expands in the UK
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Former L’Oréal Exec Joins Glossier
    Lancôme Reveals New Global Sustainability Program
    First-Ever Skincare Line Focuses on Iron To Prevent Aging
    Happi

    Latest Breaking News From Happi

    P&G Emphasizes Small Actions at Home To Be More Sustainable
    L'Oréal's Sales Jump on Gains in China and E-Commerce
    PCPC Virtual Summit Features Legal & Regulatory Conference
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    TLMI reveals Eugene Singer Award winners at Virtual Spring Summit
    Monadnock Paper Mills joins SGP
    ACTEGA helps converter reach sustainability goals
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Albaad to Add Natural-Based Line in Israel
    First Quality to Discontinue Tampon Operations
    Jessup Installs New Era Coating and Laminating Line
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    BioMagnetic Sciences Names President and CEO
    Mainstay Medical Launches ReActiv8 in Australia
    Biogennix Rolls Out Agilon Strip Bone Graft
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence
    LG Display Cuts Down CO2-eq Emissions by 3 Million Tons in 2020
    European Commission's Innovation Radar Acknowledges 3 ARMOR Innovations

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login